Advertisement

Search Results

Advertisement



Your search for Jedd D. Wolchok, MD, PhD matches 14 pages

Showing 1 - 14


2018 Fellows of the American Society of Clinical Oncology (FASCO) Recognized During Annual Meeting in Chicago

The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, the individuals at risk for, or with...

symptom management
immunotherapy

ASCO Clinical Practice Guideline on Managing Immune-Related Adverse Events: Next Big Step for Immune Checkpoint Inhibitors

The publication of the ASCO clinical practice guideline for the management of immune therapy–related adverse events—reviewed in this issue of The ASCO Post—represents an important next step in the incorporation of checkpoint blocking antibodies as standard cancer treatment modalities.1 The U.S....

ASCO Honors Leaders in Cancer Care With 2018 Special Awards

ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform...

Featured Lectures Presented at Society of Surgical Oncology

James Ewing Lecture: Jedd D. Wolchok, MD, PhD, presented the 2017 James Ewing Lecture on “Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms.” Dr. Wolchok is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics...

Taubman Prize Jointly Awarded to Suzanne L. Topalian, MD, and Jedd D. Wolchok, MD, PhD, for Groundbreaking Work in Cancer Immunotherapy

Two clinician-scientists whose groundbreaking work has shown how the human body’s own immune system can fend off cancer will share the 2016 $100,000 Taubman Prize for Excellence in Translational Medical Science, the University of Michigan’s A. Alfred Taubman Medical Research Institute announced....

Expert Point of View: Jedd D. Wolchok, MD, PhD

“We are at a fortunate time to have multiple routes to ‘lifetime’ (T-cell) memory (including ipilimumab [Yervoy] and nivolumab [Opdivo]),” said Jedd D. Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, who was the formal discussant of the CA909-003 trial at the American...

breast cancer
issues in oncology
survivorship

Breakthroughs in Targeted Therapies for Breast Cancer Are Improving Patient Survival Rates 

For more than 20 years, José Baselga, MD, PhD, has devoted his medical and scientific career to caring for breast cancer patients and the development of novel molecular targeted agents to treat the disease. From 1996 to 2010, he was Head of the Oncology Department of Vall d’Hebron University...

solid tumors

Impressive Results Shown for Immune Checkpoint Inhibitors: Anti-PD1 and Anti-PD-L1 Antibodies 

Antibody-mediated blockade of the programmed death 1 protein (PD-1) and its ligand (PD-L1) resulted in potent and durable tumor regression and prolonged stabilization of disease in patients with advanced solid tumors, according to early data on these drugs presented at the 2013 ASCO Annual Meeting. ...

skin cancer

Concurrent Immunotherapy Pays Off in Advanced Melanoma

In advanced melanoma, two immune checkpoint inhibitors may be better than one, according to the promising outcomes of a study reported at the 2014 ASCO Annual Meeting. Concurrent treatment with the anti–CTLA-4 antibody ipilimumab (Yervoy) and nivolumab, an antibody targeting the programmed death...

skin cancer

Survival Benefits of Front-Line Treatment With Nivolumab for Advanced Melanoma Confirmed, Yet Questions Remain

As reported in this issue of The ASCO Post, Robert and colleagues recently published a phase III study comparing the anti–programmed death 1 (PD-1) antibody nivolumab with the standard melanoma chemotherapy dacarbazine in the front-line treatment of patients with advanced BRAF wild-type melanoma.1...

2015 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with more than 28,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees, and thank them for their time and ...

skin cancer

Addition of Nivolumab to Ipilimumab Improves Response Rate and Progression-Free Survival in Previously Untreated Advanced Melanoma

In a phase II study reported in The New England Journal of Medicine, Postow et al found that dual checkpoint inhibitor therapy with the anti–CTLA-4 antibody ipilimumab (Yervoy) and the anti–PD-1 monoclonal antibody nivolumab (Opdivo) produced greater response rates and prolonged...

skin cancer
issues in oncology

Somatic Tumor Neoepitopes as Basis for Response to CTLA-4 Inhibition in Melanoma

The molecular determinants of benefit from immune checkpoint inhibitor treatment have not been characterized. In a study reported in The New England Journal of Medicine, Snyder et al found that benefit of the anti–cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies ipilimumab (Yervoy) and...

skin cancer

ASCO 2013: Phase I Trial Suggests Ipilimumab and PD-1 Drug Nivolumab May Be Better Together than Alone for Advanced Melanoma

Results from a phase I study show that combination therapy with ipilimumab (Yervoy) and the investigational antibody drug nivolumab led to lasting tumor shrinkage in approximately half of patients with aggressive, advanced melanoma. The results will be presented at the 2013 ASCO Annual Meeting in...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.